Sodium Sulfate/Magnesium Sulfate/Potassium Chloride

WEEKLY REPORT 11/15 2024 产业简报 本期导读 本周要闻 产业洞察 产业研报 近期活动 最新课程 本 周 要 闻 SHINE CONSULTANT 行业快讯 News Flashes 国家医保局发布多批立项指南新增哪些“适老化”价格项目 近日，国家医保局发布多批立项指南，新增“适老化”价格项目，鼓励支持医疗机构为老年人提供多元优质医疗服务，整合康复项目，推动人工智能技术在康复中应用，并规定单人间病房床位费市场调节价，以满足老年患者需求。（中国经济网等） 首付42.5亿！默沙东拿下中国PD-(L)1/VEGF双抗管线 11月14日，默沙东宣布与礼新医药达成协议，获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可权利。 根据协议条款，礼新医药已授权默沙东LM-299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款（注：交易总金额32.88亿美元，折合人民币约238亿元）。该交易预计将于2024年第四季度完成。（动脉新医药 ） 诚达药业达格列净原料药通过CDE审批 11月14日晚间，诚达药业（301201）发布公告称，公司收到国家药品监督管理局核准签发的达格列净原料药《化学原料药上市申请批准通知书》。诚达药业表示，达格列净原料药通过CDE技术审评，证明该原料药已符合国家相关药品审评技术标准，可销售至国内市场，将进一步丰富公司的产品线，有助于拓展公司业务领域，有利于进一步扩展公司原料药制剂一体化生产范围，增强公司一体化生产的优势。（北京商报） 京东健康(06618)发布第三季度业绩，经营盈利5.52亿元，同比增长216% 京东健康(06618)发布2024年第三季度业绩，收入133.02亿元(人民币，下同)，同比增长14.8%;经营盈利5.52亿元，同比增长216%。截至2024年9月30日止三个月内，京东健康不断深化与药企的合作，多款新药相继在京东大药房实现首发上线，包括海思科旗下全球首款超长效降糖药倍长平®、诺华制药旗下罕见病药品飞赫达®、欧加隆旗下降脂药益立妥® 等。京东健康还充分发挥自身供应链资源优势，助力药企建立高效的药品流通体系和新型数字化商业模式。（智通财经APP） 步长制药：子公司复方硫酸钠片药品临床试验申请获受理 步长制药(603858)11月13日晚间公告，公司近日获悉，公司全资子公司保定天浩制药有限公司的“复方硫酸钠片”药品注册临床试验申请获国家药监局的受理，并收到《受理通知书》。复方硫酸钠片适用于成人肠镜检查前的结肠清洁。（证券时报） 人事变动 Personnel Changes 中国医药：车凌云先生申请辞去公司董事及董事会专门委员会相关职务 中国医药11月13日晚间发布公告称，因工作调整原因，车凌云先生申请辞去公司董事及董事会专门委员会相关职务，并不再担任公司任何职务。（每日经济新闻） 天津医药：冯煌任董事长，张旺任副董事长 天津市医药集团有限公司公告，根据公司法及公司章程规定，拟选举冯煌、王东、张旺、徐阳雪、王光华为公司董事，陈津竹不再担任公司董事长、董事职务，滕飞不再担任公司副董事长、董事职务，张铭芮、孙利军、于克祥不再担任公司董事职务；选举冯煌担任公司董事长，张旺担任公司副董事长，赵忱担任公司监事会主席。（金融界AI电报） 产 业 洞 察 SHINE CONSULTANT 01 Leqvio大卖5.31亿美元！小核酸赛道“大药时代”，7款“重磅”潜力药物还在路上 点击阅读全文 产 业 研 报 SHINE CONSULTANT 01 2023年中国企业医疗健康管理白皮书 02 2022年中国康复医疗行业研究报告 03 合成生物学产业链及应用场景 04 2023年家用医疗智能器械商业路径发展报告 05 医疗产业链中数字化场景发展现况及挑战 06 2022年药品市场生命周期研究之GLP-1RA篇 07 中国医疗器械蓝皮书（2023版） 点击阅读全文 近 期 活 动 SHINE CONSULTANT 2025 APRL 第十三届亚洲医药研发领袖峰会，2月26日-27日 · 上海（点击查看） 最 新 课 程 SHINE CONSULTANT 生物医药行业研究与投资逻辑（点击查看） 全面汇总：医药全行业研究分析框架与投资逻辑详解（点击查看） 联系我们 Sunny Sun 孙女士 T:021 6095 7205 M:189 6294 0579（微信同号） E:sunny.sun@shine-consultant.com 会议咨询 媒体合作 商务合作 欢迎详询洽谈！ SHINE CONSULTANT 上海士研管理咨询有限公司成立于2005年，致力于为组织领导者提供沟通交流与专家智库平台。通过二十年沉淀与积累，覆盖了金融与投资、交通与运输、消费与文旅、医药与医疗、能源与资源、高科与电信、公用与政府等产业领域，服务着全球500强和万余家领导型企业，汇聚了百万余名机构决策者，并与千余家产业权威机构建立了战略伙伴关系。士研咨询秉承专业立身的理念发展队伍，现拥有百余名专业的资深人员，核心管理团队都具有十五年以上的专业经验。

SUFLAVE™ offers the same efficacy as SUPREP® Bowel Prep Kit BRAINTREE, Mass., June 22, 2023 /PRNewswire/ -- Sebela Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted approval of SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults. SUFLAVE, a low-volume, safe and effective colonoscopy preparation – with a taste similar to a lemon-lime sports drink – was developed and will be marketed by Braintree Laboratories, a leader in gastroenterology and part of Sebela Pharmaceuticals. The current active screening rate in the United States for colorectal cancer (CRC) is 72%, leaving 28% unscreened, which contributes to 153,000 CRC diagnoses and more than 52,000 deaths annually.i,ii Colonoscopy is the most common detection method for colorectal cancer, a leading cause of cancer-related deaths that can be managed more effectively through screening and early detection.iii Successful colonoscopy screening is dependent upon adequate cleansing of the colon.iv Despite this, available methods of liquid preparation are not widely accepted by patients due to large volumes of poor-tasting solutions, resulting in low patient compliance and the need for repeat screenings. Additionally, colonoscopy preparation products and processes are commonly cited as a significant patient barrier to colon cancer screening,v reinforcing an unmet need among patients for better bowel preparation options. Tolerance of bowel preparation remains the largest deterrent for patients considering screening colonoscopy with 71% of patients saying it's the worst part of colonoscopy and 55% indicating it was the greatest deterrent to a future colonoscopy.vi Prep volume, palatability and patient education are three key factors in reducing prep hesitancy. "Patients frequently struggle with the taste and volume of traditional bowel preparations – and fear related to the preparation can also negatively impact patient willingness to undergo follow-up colonoscopy if it is indicated," said Douglas K. Rex, M.D., Distinguished Professor Emeritus at Indiana University School of Medicine and a full time practicing clinical gastroenterologist. "I believe the palatable lemon-lime flavor of SUFLAVE will be a welcomed option for patients – reducing preparation hesitancy and giving more people the chance to feel comfortable during preparation and getting a successful and effective procedure." In a head-to-head pivotal study versus SUPREP® Bowel Prep Kit, (sodium sulfate, potassium sulfate, and magnesium sulfate) Oral Solution, 94% of patients achieved successful bowel cleansing with SUFLAVE. The majority of patients reported that SUFLAVE tastes like a sports drink, and 79% of patients found the taste neutral to very pleasant compared to SUPREP (54%). Additionally, 87% of patients found SUFLAVE tolerable to very easy to consume, and 80% of patients reported that they would ask for SUFLAVE for a subsequent colonoscopy. Rates of gastrointestinal adverse events with SUFLAVE were low (<8%).vii "We believe in patient choice and are committed to improving the colon preparation process for patients. We are delighted with the FDA's approval of SUFLAVE – which has efficacy equivalent to SUPREP, but with taste similar to a sports drink," said Alan Cooke, President and CEO of Sebela Pharmaceuticals. "We are proud of the hard work and dedication of the Braintree team and the phase 3 trials investigator group who continue to bring new, better choices to people undergoing colonoscopy screening." SUFLAVE is the latest innovation in colonoscopy preparation from Braintree Laboratories. In November 2020, the FDA approved the company's tablet preparation, SUTAB®, which has had an excellent adoption record with use by over 2 million patients. SUFLAVE will be available by prescription to patients in the U.S. in early August. IMPORTANT SAFETY INFORMATION SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. DOSAGE AND ADMINISTRATION: A low residue breakfast may be consumed on the day before colonoscopy, followed by clear liquids up to 2 hours prior to colonoscopy. Administration of two doses of SUFLAVE are required for a complete preparation for colonoscopy. Each bottle must be reconstituted with water before ingestion. Each bottle and one flavor-enhancing packet are equivalent to one dose. An additional 16 ounces of water must be consumed after each dose. Stop consumption of all fluids at least 2 hours before the colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: Gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUFLAVE. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration; Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur. ADVERSE REACTIONS: Most common adverse reactions (> 2%) are: nausea, abdominal distension, vomiting, abdominal pain, and headache. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance. See Full Prescribing Information and Medication Guide About Sebela Pharmaceuticals Sebela Pharmaceuticals is a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women's health. Braintree, a part of Sebela Pharmaceuticals, is the market leader in colonoscopy screening for over 35 years, having invented, developed and commercialized a broad portfolio of innovative prescription colonoscopy preparations and multiple gastroenterology products. Braintree also has multiple gastroenterology programs in late-stage clinical development including Tegoprazan which is in phase 3 trials for gastro-esophageal reflux disease (GERD), specifically, erosive esophagitis (EE) and non-erosive reflux disease (NERD). In addition, Sebela Women's Health has two next generation intra-uterine devices (IUDs) for contraception in the final stages of clinical development. Sebela Pharmaceuticals has offices/operations in Roswell, GA; Braintree, MA; and Dublin, Ireland; has annual net sales of approximately $200 million; and has grown to over 320 employees through strategic acquisitions and organic growth. Please visit sebelapharma.com for more information or call 800-874-6756. Forward-looking Statements This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of SUFLAVE™; growth and opportunity, including peak sales and the potential demand for SUFLAVE™, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a growing concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Sebela Pharmaceuticals does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law. For further information, contact: Logan Campbell, Red Havas [email protected] 1-724-987-2781 ______________ i Centers for Disease Control and Prevention. (2023, March 22). Colorectal (colon) cancer statistics. Center for Disease Control and Prevention. Retrieved June 12, 2023, from ii Colorectal cancer – statistics. Cancer.net (2023, February). Retrieved June 12, 2023, from iii Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67(2):291-298 iv Harrison, N. M., & Hjelkrem, M. C. (2016). Bowel cleansing before colonoscopy: Balancing efficacy, safety, cost and patient tolerance. World journal of gastrointestinal endoscopy, 8(1), 4–12. v Romero, R. V., & Mahadeva, S. (2013). Factors influencing quality of bowel preparation for colonoscopy. World journal of gastrointestinal endoscopy, 5(2), 39–46. vi emulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. J Clin Gastroenterol. 2023 Apr 1;57(4):400-403. doi: 10.1097/MCG.0000000000001689. PMID: 35324481. vii Data on File, Braintree, MA: Braintree Laboratories, Inc. SOURCE Sebela Pharmaceuticals